Keith Leonard, M.S., M.B.A.
President and Chief Executive Officer, Co-founder

Keith Leonard was formerly Senior Vice President and General Manager of Amgen Europe responsible for all commercial operations in 28 countries. During his tenure in Europe he built a team that took the company’s products to market leadership in oncology and nephrology, and dramatically expanded the company’s operations, in just three years. Prior to that experience, his career at Amgen included establishing Amgen’s presence in rheumatology with the creation of the Rheumatology Business Unit, Head of Information Management, and leadership roles in Sales and Marketing, Engineering, Operations, and Finance. Keith is a member of the Board of Directors of Affymax, Inc. (AFFY) and a former Director of ARYx Therapeutics, and served as a commissioned officer in the US Navy.

Keith holds a BS in Engineering from the University of California, Los Angeles (UCLA); a BA in History from the University of Maryland; an MS in Engineering from the University of California, Berkeley; and an MBA from the Anderson School of Management at UCLA.

Deepak Chadha, M.S., M.B.A., R.A.C.
Vice President, Regulatory Affairs

Deepak Chadha brings to KYTHERA more than 15 years of experience in regulatory submissions and projects for drugs, biologics, medical devices and combination products. His most recent role was Vice President, Global Regulatory Affairs at Allergan Medical (formerly know as Inamed Corporation), where he helped build the Global Regulatory Affairs Department and was responsible for developing and implementing global regulatory strategies. Deepak led the group to successful submission and approval of aesthetic products in the U.S. and overseas. Prior to Allergan, Deepak held positions of increasing responsibility at Biomeasure Inc. (Ipsen) and Stryker Biotech in Massachusetts. At Biomeasure Inc., he oversaw the U.S. regulatory activities of Ipsen’s Botulinum Toxin Type-A development program for the aesthetic indication. His regulatory experience encompasses preparation and successful submission of clinical and marketing applications to the FDA, the EMEA, as well as the regulatory agencies of the United Kingdom, Canada, Australia, and Japan among others.

Deepak holds a BS in Pharmaceutical Sciences from Berhampur University in Orissa, India: an MS in Pharmaceutics from Hamdard University in New Delhi, India: and an MBA in International Business from California State University, Dominguez Hills.

Pierre J.G. Corin, M.S.
Vice President, Global Clinical Operations

Pierre Corin brings to KYTHERA more than 20 years of experience in the pharmaceutical industry focusing on clinical operations and management of large international trials, including specific expertise in aesthetic medicine. Most recently, he served as Director of Clinical Development at Allergan Medical, where he led a multidisciplinary project team and directed the Breast Implant Follow-Up Study (BIFS) for reconstructive and aesthetic surgery. The BIFS program is the largest international post-approval study of its kind. Pierre has led many global initiatives, in a variety of therapeutic areas. Prior to Allergan Medical, Pierre held senior positions at several global Contract Research Organizations (CROs) and large Pharmaceutical companies including PPD Development where he was responsible for trials about Women Health and Dermatology, Covance, Inc., ClinTrials Research Ltd., Innovex, Inc. and Glaxo. He started his career with Bristol-Myers Squibb in the Sales and Marketing department.

Pierre holds a Masters of Science Degree from the University of Liege in Belgium.

Nancy Jorgesen, M.A., M.B.A.
Vice President, Product, Systems and Alliance Management

Nancy Jorgesen has served as KYTHERA's ATX-101 Product Development Team Leader for the last five years and is responsible for managing the company's partnership with Bayer Dermatology. She has almost 20 years experience in the biotech industry, including overseeing the project management components required to advance products from early stage development through commercialization. Nancy was previously with Amgen for over 10 years, where she held roles of increasing responsibility in Rheumatology product development, corporate process improvement/change management and molecular biology/protein chemistry research. In addition, she was a Product Development Team leader within the Animal Health unit of Dow AgroSciences, focusing on the development of edible vaccines.

Nancy earned an MA in Biochemistry/Molecular Biology and a BA in Microbiology from the University of California at Santa Barbara and an MBA in Finance and Business Strategy from the University of Illinois at Urbana-Champaign.

Keith Klein, J.D.
General Counsel

Keith Klein formerly spent more than 15 years in Amgen’s law department where he ultimately served as senior associate general counsel, responsible for legal activities relating to the areas of sales and marketing, federal government affairs, corporate relationships, manufacturing, product supply and product development. Before Amgen, Keith was a corporate associate at Cooley Godward Castro Huddleson & Tatum, where he advised companies on protection of trade secrets, intellectual property rights, negotiation of technology licenses and transfers, and represented both issuers and investors in public offerings, mergers and acquisitions.

Keith holds a BA in Economics from University of California, Los Angeles and a law degree with honors from University of California, Davis.

Serge Lichtsteiner, Ph.D.
Vice President, Research

Serge Lichtsteiner, PhD, has over 15 years of experience in drug discovery and development. Most recently, he spent over 6 years at Cytokinetics, Inc. where, as Director of Lead Discovery and Molecular Biology, he headed multiple functional teams responsible for generating the company’s robust product pipeline and supporting all early stages of drug discovery efforts. Prior to Cytokinetics, Serge was Associate Director, Head of Molecular Biology at Pfizer Global R&D where he led a team focused on providing engineered, recombinant proteins to enable target validation and lead optimization.

Serge holds numerous pending and issued patents in oncology, drug discovery technology, and protein chemistry. He holds a BS in Biology, an MS in Molecular Biology and a PhD in Molecular Biology, all from the University of Geneva in Switzerland. Before beginning his career in the biopharmaceutical world, Serge was a postdoctoral scientist in the Molecular and Cell Biology department at UC Berkeley.

He is currently a Visiting Scholar at the California NanoSystems Institute (CNSI) at UCLA.

Susan Lundeen
Vice President, Human Resources

Susan Lundeen brings more than 20 years of experience in generalist and specialist human resource functions. Prior to joining KYTHERA, Susan was Vice President of Human Resources and Administration at Activus Healthcare Solutions, Inc., where she designed people systems and decision-making processes in support of a differentiated sales model and technology-focused healthcare distributor. Before Activus, Susan spent more than 12 years at Amgen where she advanced rapidly through human resource management positions in the U.S. and Europe. Most recently, she served as Senior Director of Human Resources responsible for Strategic Sourcing and Staffing.

Susan has a BA in Psychology and Business Administration from California Lutheran University and currently sits on the Board of Regents for the University.

John Smither, C.P.A.
Chief Financial Officer

John Smither brings to KYTHERA more than 30 years of experience in finance and accounting. Most recently, he spent more than 9 years at Amgen where he advanced rapidly through financial management positions for business units and subsidiaries based in Europe and the US. During his term as Chief Financial Officer of Amgen Europe, Smither directed financial planning, accounting, cost accounting, treasury, cash management and financial reporting under U.S. GAAP in 25 European countries. Other roles at Amgen included Head of Internal Audit and Executive Director of Corporate Accounting at Amgen where he was responsible for accounting operations including the selection and implementation planning of SAP’s business enterprise software. Prior to Amgen, Smither was an audit partner at Ernst & Young in Los Angeles, the Chief Financial Officer of several early stage industrial companies and a former member of the Board of Directors of Dompe Biotec S.p.A.

Smither holds a BS in Accounting from California State University at Los Angeles. He is a Certified Public Accountant and a member of the American Institute of Certified Public Accountants (AICPA), the California Society of Certified Public Accountants (CSCPA) and Financial Executives International (FEI).

Patricia “Patty” Walker, M.D., Ph.D.
Chief Medical Officer

Patty Walker was formerly Executive Vice President and Chief Science Officer responsible for research, development and regulatory affairs at Allergan Medical (formerly known as Inamed Corporation). Prior to joining Inamed, Patty was Vice President, Clinical Research and Development for skin care pharmaceuticals at Allergan, Inc. Over the past 10 years, Patty has led key product approvals in dermatology and aesthetic medicine including the development and approval of Tazorac^®, BOTOX^® Cosmetic, Hylaform^®, Captique^®, Juvederm, Bioenterics^® LAP-BAND^® and Inamed^® Silicone gel-filled Breast Implants[1].

Patty earned her MD/PhD (Physiology and Biophysics) at the University of Iowa. Following her degrees she completed a residency in Dermatology and a research fellowship in the Dermatology Branch, National Cancer Institute at the National Institute of Health (NIH). Patty is a board certified Dermatologist.

Jeff Webster
Vice President, Operations

Jeff Webster, a 19-year Amgen veteran, has held positions of increasing responsibility in process development, engineering, investor relations, European marketing, product development, portfolio management, corporate development and strategy, and operations. As the product development team leader for NEUPOGEN^®/NEULASTA^®[2], Webster oversaw multiple regulatory filings in US, Europe, Canada and Australia and led efforts to expand the clinical and commercial footprint of this important medicine. In his most recent position as Vice President, Operations Planning at Amgen, Webster led an 85-person group in product development, project management, training and development, and strategy functions within the Operations function.

Webster holds a Masters in Business Administration from San Jose State University and a Bachelor of Science in Chemical Engineering from University of California, Berkeley.